ReviewInternational journal of molecular sciences2016
Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Exercise interventions for adults after liver transplantation.The Cochrane database of systematic reviews · 2023Pooled it
- Metabolic comorbidities and post-transplant outcomes in Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD): a cohort study from a Brazilian tertiary center.Archives of endocrinology and metabolism · 2025Article
- Ramadan Fasting and Complications of Metabolic Dysfunction-Associated Steatotic Liver Disease: Impacts on Liver Cirrhosis and Heart Failure.Journal of clinical medicine · 2025Review
- Ramadan Fasting in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Transplant, and Bariatric Surgery: A Narrative Review.Journal of clinical medicine · 2024Review
- The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients.Biomedicines · 2023Review
- MAFLD was more easily diagnosed than NAFLD in liver transplant recipients with abnormal liver function.iLIVER · 2022Article
- Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients.Hepatobiliary surgery and nutrition · 2022Review
- Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic.World journal of clinical cases · 2021Review
- Salivary Biomarkers and Oral Health in Liver Transplant Recipients, with an Emphasis on Diabetes.Diagnostics (Basel, Switzerland) · 2021Article
- Noninvasive markers of liver steatosis and fibrosis after liver transplantation - Where do we stand?World journal of transplantation · 2021Review
- Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation.Translational gastroenterology and hepatology · 2020Review
- Warm ischemia time and elevated serum uric acid are associated with metabolic syndrome after liver transplantation with donation after cardiac death.World journal of gastroenterology · 2018Article
- Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?World journal of gastroenterology · 2018Review
- Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Review
- NAFLD: Is There Anything New under the Sun?International journal of molecular sciences · 2017Article
- Non-alcoholic fatty liver disease: An expanded review.World journal of hepatology · 2017Review
- Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do.World journal of hepatology · 2017Review
- Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplant is the unique curative therapy for patients with acute liver failure or end-stage liver disease, with or without hepatocellular carcinoma. Increase of body weight, onset of insulin resistance and drug-induced alterations of metabolism are reported in liver transplant recipients. In this context, post-transplant diabetes mellitus, hyperlipidemia, and arterial hypertension can be often diagnosed. Multifactorial illnesses occurring in the post-transplant period represent significant causes of morbidity and mortality. This is especially true for metabolic syndrome. Non-alcoholic steatosis and steatohepatitis are hepatic manifestations of metabolic syndrome and after liver transplant both recurrent and de novo steatosis can be found. Usually, post-transplant steatosis shows an indolent outcome with few cases of fibrosis progression. However, in the post-transplant setting, both metabolic syndrome and steatosis might play a key role in the stratification of morbidity and mortality risk, being commonly associated with cardiovascular disease. The single components of metabolic syndrome can be treated with targeted drugs while lifestyle intervention is the only reasonable therapeutic approach for transplant patients with non-alcoholic steatosis or steatohepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.